All In MedTech

Device Trial Radar · NCT03765307

Bronchial Ablation for Treatment of Asthma (BATA) Trial

Safety and Efficacy of the SyMap Bronchial Ablation System for Treatment of Severe Asthma: A Prospective, Multicenter, Randomized Controlled Clinical Trial (Bronchial Ablation for Treatment of Asthma (BATA) Trial)

Last checked: Nov 20, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Actual

Start

Jun 18, 2019

Primary completion

Aug 15, 2024

Study completion Dec 31, 2028

Sponsor

Lead sponsor
SyMap Medical (Suzhou), Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
JieNuo Medical(Beijing)Co.,Ltd
First posted
Dec 5, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of a bronchial radiofrequency ablation system (SyMap Medical (Suzhou) Ltd) in a population of subjects with severe asthma who are still symptomatic despite being managed on high-dose Inhaled Corticosteroids (ICS) and Long-Acting β2-adrenergic Agonists (LABA).

Conditions

  • Asthma

Interventions

  • SyMap Bronchial Ablation SystemDevice

    The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.

  • Boston Scientific Alair SystemDevice

    The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of severe asthma exacerbations per year (the number of severe asthma exacerbations per person per year)Time frame: 12 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese Pla General Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • University of Chinese Academy of Sciences Shenzhen Hospital

    Shenzhen, Guangdong, China

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.